Legal Representation
Attorney
Matthew P. Hintz, Esq.
USPTO Deadlines
Next Deadline
48 days remaining
Non-Final Action E-Mailed
Due Date
February 18, 2026
Extension Available
Until May 18, 2026
Application History
12 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 18, 2025 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Dec 17, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Dec 17, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Dec 17, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Nov 18, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Nov 18, 2025 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Nov 18, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Nov 18, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Nov 7, 2025 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Nov 7, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jun 30, 2025 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Jun 30, 2025 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of ophthalmic diseases and conditions; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of glaucoma, dry eye disease, macular degeneration, and lowering intraocular pressure, namely, ophthalmic pharmaceutical preparations that are delivered using implantable intravitreal drug delivery devices that are filled and sold with ophthalmic pharmaceutical preparations; Pharmaceutical preparations for the treatment of glaucoma, dry eye disease, and macular degeneration; Pharmaceutical preparations for the treatment of lowering intraocular pressure; Pharmaceutical preparations for the treatment of eye diseases and conditions, namely, dexamethasone that is delivered using implantable intravitreal drug delivery devices that are filled and sold with dexamethasone; Pharmaceutical preparations for the treatment of post-op pain and inflammation of the eye, and itching associated with allergic conjunctivitis, namely dexamethasone that is delivered using implantable intravitreal drug delivery devices that are filled and sold with dexamethasone; Ophthalmic preparations
Class 042
Research and development in the field of pharmaceuticals and biopharmaceuticals; Product development in the field of pharmaceutical and biopharmaceutical preparations, inserts being implantable intravitreal drug delivery devices, implants, and medicines; Development of pharmaceutical preparations and medicines; Product development in the field of pharmaceuticals and biopharmaceuticals
Additional Information
Design Mark
The mark consists of the word OCULAR positioned above the stylized word THERAPEUTIX. Above and below the letter O, there are two curved rows of small circles, forming in combination with the letter "O," a stylized representation of an eye.
Classification
International Classes
005
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
OCULAR THERAPEUTICS